EyePoint Pharmaceuticals (EYPT) Short Interest Ratio & Short Volume → AI finds its first serious application (From Wall Street Star) (Ad) Free EYPT Stock Alerts $17.81 +1.06 (+6.33%) (As of 03:39 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media EyePoint Pharmaceuticals Short Interest DataCurrent Short Volume6,540,000 sharesPrevious Short Volume6,850,000 sharesChange Vs. Previous Month-4.53%Dollar Volume Sold Short$139.17 millionShort Interest Ratio / Days to Cover6.7Last Record DateApril 15, 2024Outstanding Shares49,830,000 sharesPercentage of Shares Shorted13.12%Today's Trading Volume568,628 sharesAverage Trading Volume995,385 sharesToday's Volume Vs. Average57% Short Selling EyePoint Pharmaceuticals ? Sign up to receive the latest short interest report for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatEYPT Short Interest Over TimeEYPT Days to Cover Over TimeEYPT Percentage of Float Shorted Over Time Ad The Bull ReportHealthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic EyePoint Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20246,540,000 shares $139.17 million -4.5%N/A6.7 $21.28 3/31/20246,850,000 shares $141.59 million +4.1%N/A7.1 $20.67 3/15/20246,580,000 shares $141.34 million +15.0%N/A6.4 $21.48 2/29/20245,720,000 shares $155.64 million +20.4%N/A4.5 $27.21 2/15/20244,750,000 shares $138.13 million -7.6%N/A2.9 $29.08 1/31/20245,140,000 shares $138.42 million -1.2%N/A3.3 $26.93 Get the Latest News and Ratings for EYPT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/20245,200,000 shares $118.35 million -2.4%N/A3.5 $22.76 12/31/20235,330,000 shares $123.18 million +12.2%N/A3.9 $23.11 12/15/20234,750,000 shares $92.86 million -32.2%N/A3.6 $19.55 11/30/20237,010,000 shares $43.81 million +28.9%25.0%5.9 $6.25 11/15/20235,440,000 shares $36.39 million +1.7%19.4%10.3 $6.69 10/31/20235,350,000 shares $32.21 million +9.0%19.2%10.3 $6.02 10/15/20234,910,000 shares $39.77 million -29.3%17.6%9.3 $8.10 9/30/20236,940,000 shares $55.45 million +12.3%25.1%11.6 $7.99 9/15/20236,180,000 shares $64.77 million +9.2%22.3%10.2 $10.48 8/31/20235,660,000 shares $56.09 million +12.1%20.6%9.5 $9.91 8/15/20235,050,000 shares $71.66 million +3.7%18.8%8.9 $14.19 7/31/20234,870,000 shares $60.88 million +1.9%N/A9.3 $12.50 7/15/20234,780,000 shares $52.44 million -7.7%N/A4.9 $10.97 6/30/20235,180,000 shares $45.07 million +7.5%N/A5.6 $8.70 6/15/20234,820,000 shares $32.73 million +13.2%18.4%5.3 $6.79 5/31/20234,260,000 shares $25.77 million +5.2%16.2%4.8 $6.05 5/15/20234,050,000 shares $24.30 million +11.3%15.4%4.7 $6.00 4/30/20233,640,000 shares $22.86 million -0.3%14.1%4.4 $6.28 4/15/20233,650,000 shares $15.80 million +9.3%14.2%5.3 $4.33 3/31/20233,340,000 shares $9.82 million +19.7%13.0%11 $2.94 3/15/20232,790,000 shares $6.67 million +34.8%10.9%10 $2.39 2/28/20232,070,000 shares $6.91 million No Change8.1%8.1 $3.34 2/15/20232,070,000 shares $7.66 million -4.2%8.1%8.5 $3.70 1/31/20232,160,000 shares $10.07 million +6.9%8.6%9.3 $4.66 1/15/20232,020,000 shares $10.18 million +13.5%8.0%9.4 $5.04 12/30/20221,780,000 shares $6.23 million +6.0%7.1%12.3 $3.50 12/15/20221,680,000 shares $4.50 million -2.9%6.7%11.6 $2.68 11/30/20221,730,000 shares $5.54 million -3.4%6.9%13.6 $3.20 11/15/20221,790,000 shares $7.91 million -9.1%7.1%14.1 $4.42 10/31/20221,970,000 shares $10.64 million -1.5%N/A16.1 $5.40 10/15/20222,000,000 shares $11.20 million -1.5%7.7%14.3 $5.60 9/30/20222,030,000 shares $16.06 million -0.5%7.8%12.5 $7.91 9/15/20222,040,000 shares $16.30 million +0.5%7.9%12.7 $7.99 8/31/20222,030,000 shares $20.30 million +1.5%7.8%12.7 $10.00Healthcare Takes A Big Step Forward With The Help Of AI (Ad)The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic EYPT Short Interest - Frequently Asked Questions What is EyePoint Pharmaceuticals' current short interest? Short interest is the volume of EyePoint Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 6,540,000 shares of EYPT short. Learn More on EyePoint Pharmaceuticals' current short interest. What is a good short interest ratio for EyePoint Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EYPT shares currently have a short interest ratio of 7.0. Learn More on EyePoint Pharmaceuticals's short interest ratio. Which institutional investors are shorting EyePoint Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of EyePoint Pharmaceuticals: Perceptive Advisors LLC, Affinity Asset Advisors LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is EyePoint Pharmaceuticals' short interest increasing or decreasing? EyePoint Pharmaceuticals saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 6,540,000 shares, a decline of 4.5% from the previous total of 6,850,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does EyePoint Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies compare to EyePoint Pharmaceuticals: Cytek Biosciences, Inc. (6.29%), Standard BioTools Inc. (3.05%), Quanterix Co. (3.21%), Pacific Biosciences of California, Inc. (18.11%), Nautilus Biotechnology, Inc. (1.95%), Harvard Bioscience, Inc. (1.55%), Bionano Genomics, Inc. (8.85%), Accelerate Diagnostics, Inc. (2.90%), Olink Holding AB (publ) (2.20%), 10x Genomics, Inc. (7.44%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short EyePoint Pharmaceuticals stock? Short selling EYPT is an investing strategy that aims to generate trading profit from EyePoint Pharmaceuticals as its price is falling. EYPT shares are trading up $0.38 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against EyePoint Pharmaceuticals? A short squeeze for EyePoint Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EYPT, which in turn drives the price of the stock up even further. How often is EyePoint Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EYPT, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Cytek Biosciences Short Interest Standard BioTools Short Interest Quanterix Short Interest Pacific Biosciences of California Short Interest Nautilus Biotechnology Short Interest Harvard Bioscience Short Interest Bionano Genomics Short Interest Accelerate Diagnostics Short Interest Olink Holding AB (publ) Short Interest 10x Genomics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EYPT) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press4 coins to be the “Next Bitcoin”True Market Insiders